NOVEL AMORPHOUS ACTIVE PHARMACEUTICAL INGREDIENTS COMPRISING SUBSTANTIALLY AMORPHOUS MESOPOROUS MAGNESIUM CARBONATE

The present invention is directed to a solid and substantially amorphous active pharmaceutical ingredient, to an oral pharmaceutical formulation comprising said substantially amorphous active pharmaceutical ingredient, as well as to a method for the manufacture of the same. The invention is also dir...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LINDMARK, Tuulikki, ARVÉN, Ottilia, ÅSBERG, Peter, FRYKSTRAND ÅNGSTRÖM, Sara
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOIDCHEMISTRY CHEMISTRY COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM,CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THERARE-EARTH METALS HUMAN NECESSITIES HYGIENE INORGANIC CHEMISTRY MEDICAL OR VETERINARY SCIENCE METALLURGY PERFORMING OPERATIONS PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES THEIR RELEVANT APPARATUS TRANSPORTING
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention is directed to a solid and substantially amorphous active pharmaceutical ingredient, to an oral pharmaceutical formulation comprising said substantially amorphous active pharmaceutical ingredient, as well as to a method for the manufacture of the same. The invention is also directed to a particulate anhydrous and substantially amorphous mesoporous magnesium carbonate(MMC), to a method for the manufacture thereof, and the use of said particulate anhydrous and substantially amorphous mesoporous magnesium carbonate (MMC)to stabilize an active pharmaceutical ingredient (API). La présente invention concerne un principe actif pharmaceutique solide et sensiblement amorphe, une formulation pharmaceutique pour la voie orale comprenant ledit principe actif pharmaceutique sensiblement amorphe, ainsi qu'un procédé de fabrication de celui-ci. L'invention concerne également un carbonate de magnésium mésoporeux (MMC, pour "mesoporous magnesium carbonate") particulaire et sensiblement amorphe, un procédé de fabrication de celui-ci, et l'utilisation dudit carbonate de magnésium mésoporeux (MMC) particulaire et sensiblement amorphe pour stabiliser un principe actif pharmaceutique (API, pour "active pharmaceutical ingredient").